Toward Bifunctional Chelators for Thallium-201 for Use in Nuclear Medicine-Reference-Cited by-同舟云学术

Toward Bifunctional Chelators for Thallium-201 for Use in Nuclear Medicine

Published:2022-07-08 Issue:7 Volume:33 Page:1422-1436
ISSN:1043-1802
Container-title:Bioconjugate Chemistry
language:en
Short-container-title:Bioconjugate Chem.

Author:

Rigby Alex¹^ORCID,Firth George¹^ORCID,Rivas Charlotte¹,Pham Truc¹,Kim Jana¹,Phanopoulos Andreas²,Wharton Luke³⁴^ORCID,Ingham Aidan³⁴,Li Lily³⁴,Ma Michelle T¹^ORCID,Orvig Chris³^ORCID,Blower Philip J.¹^ORCID,Terry Samantha Y.A.¹,Abbate Vincenzo⁵^ORCID

Affiliation:

1. School of Biomedical Engineering and Imaging Sciences, King’s College London, 4th Floor Lambeth Wing, St Thomas’ Hospital, London SE1 7EH, United Kingdom

2. Department of Chemistry, Molecular Sciences Research Hub, Imperial College London, London W12 0BZ, United Kingdom

3. Medicinal Inorganic Chemistry Group, Department of Chemistry, University of British Columbia, Vancouver, BC V6T 1Z1, Canada

4. Life Sciences Division, TRIUMF, 4004 Wesbrook Mall, Vancouver, BC V6T 2A3, Canada

5. School of Cancer & Pharmaceutical Sciences, King’s College London, Franklin-Wilkins Building, Stamford Street, London SE1 9NH, United Kingdom

Funder

Canadian Network for Research and Innovation in Machining Technology, Natural Sciences and Engineering Research Council of Canada

Wellcome Trust

Cancer Research UK

The Rosetrees Trust

EPSRC Programme Grant "MITHRAS"

Wellcome/EPSRC Centre for Medical Engineering at King?s College London

EPSRC Centre for Doctoral Training in Medical Imaging

Publisher

American Chemical Society (ACS)

Subject

Organic Chemistry,Pharmaceutical Science,Pharmacology,Biomedical Engineering,Bioengineering,Biotechnology

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.bioconjchem.2c00284

Reference45 articles.

1. Radioimmunotherapy of Prostate Cancer Using 90Y- and 177Lu-Labeled J591 Monoclonal Antibodies: Effect of Multiple Treatments on Myelotoxicity

2. Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer

3. Predictors of Overall and Disease-Free Survival in Metastatic Castration-Resistant Prostate Cancer Patients Receiving 225Ac-PSMA-617 Radioligand Therapy

4. Bone Marrow Recovery and Subsequent Chemotherapy Following Radiolabeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 in Men with Metastatic Castration-Resistant Prostate Cancer

5. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Capturing Mercury-197m/g for Auger Electron Therapy and Cancer Theranostic with Sulfur-Containing Cyclen-Based Macrocycles;Inorganic Chemistry;2024-07-18

2. Mechanisms of inclusion of thallium-201 into Prussian blue nanoparticles for nuclear medicine applications;Journal of Materials Chemistry B;2024

3. Radiochemistry: A Hot Field with Opportunities for Cool Chemistry;ACS Central Science;2023-11-14

4. Striking stability of a mixed-valence thallium(III)-thallium(I) complex in some solvents;Journal of Molecular Liquids;2023-09